Literature DB >> 17872364

Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients.

M M Vellinga1, J A Castelijns, F Barkhof, B M J Uitdehaag, C H Polman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17872364     DOI： 10.1212/01.wnl.0000265393.03231.e5

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  43 in total

1.  From injection therapies to natalizumab: views on the treatment of multiple sclerosis.

Authors:  Roberto Bomprezzi; Darin T Okuda; Yazan J Alderazi; Olaf Stüve; Elliot M Frohman
Journal:  Ther Adv Neurol Disord       Date:  2012-03       Impact factor: 6.570

2.  Post-natalizumab clinical and radiological findings in a cohort of multiple sclerosis patients: 12-month follow-up.

Authors:  Marta Melis; Eleonora Cocco; Jessica Frau; Lorena Lorefice; Giuseppe Fenu; Giancarlo Coghe; Marco Mura; Maria Giovanna Marrosu
Journal:  Neurol Sci       Date:  2013-08-30       Impact factor: 3.307

Review 3.  Monoclonal antibodies as disease modifying therapy in multiple sclerosis.

Authors:  Erin E Longbrake; Becky J Parks; Anne H Cross
Journal:  Curr Neurol Neurosci Rep       Date:  2013-11       Impact factor: 5.081

Review 4.  Monoclonal antibodies in treatment of multiple sclerosis.

Authors:  P S Rommer; A Dudesek; O Stüve; U K Zettl
Journal:  Clin Exp Immunol       Date:  2014-03       Impact factor: 4.330

Review 5.  Multiple sclerosis: Is there a safe time to discontinue therapy in MS?

Authors:  Mark S Freedman
Journal:  Nat Rev Neurol       Date:  2016-12-28       Impact factor: 42.937

6.  Rebound after Fingolimod suspension in a pediatric-onset multiple sclerosis patient.

Authors:  E Piscolla; B Hakiki; L Pastò; L Razzolini; E Portaccio; M P Amato
Journal:  J Neurol       Date:  2013-05-05       Impact factor: 4.849

7.  Fingolimod after natalizumab and the risk of short-term relapse.

Authors:  Vilija G Jokubaitis; Vivien Li; Tomas Kalincik; Guillermo Izquierdo; Suzanne Hodgkinson; Raed Alroughani; Jeannette Lechner-Scott; Alessandra Lugaresi; Pierre Duquette; Marc Girard; Michael Barnett; Francois Grand'Maison; Maria Trojano; Mark Slee; Giorgio Giuliani; Cameron Shaw; Cavit Boz; Daniele L A Spitaleri; Freek Verheul; Jodi Haartsen; Danny Liew; Helmut Butzkueven
Journal:  Neurology       Date:  2014-03-07       Impact factor: 9.910

8.  Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Group--Italian Neurological Society.

Authors:  A Ghezzi; L M E Grimaldi; M G Marrosu; C Pozzilli; G Comi; A Bertolotto; M Trojano; P Gallo; R Capra; D Centonze; E Millefiorini; S Sotgiu; V Brescia Morra; M P Amato; A Lugaresi; G Mancardi; D Caputo; E Montanari; L Provinciali; L Durelli; R Bergamaschi; P Bellantonio; M R Tola; S Cottone; G Savettieri; G Tedeschi
Journal:  Neurol Sci       Date:  2011-04       Impact factor: 3.307

Review 9.  [Progressive multifocal leukoencephalopathy. Undesirable side effect of immunotherapy].

Authors:  H-P Hartung; C Warnke; R Hohlfeld; B C Kieseier
Journal:  Nervenarzt       Date:  2009-10       Impact factor: 1.214

10.  Natalizumab in the treatment of multiple sclerosis.

Authors:  Brandon A Brown
Journal:  Ther Clin Risk Manag       Date:  2009-08-03       Impact factor: 2.423
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.